Torsdag 26 December | 18:39:19 Europe / Stockholm

Kalender

Tid*
2025-04-24 N/A Årsstämma
2025-02-26 N/A Bokslutskommuniké 2024
2025-01-06 N/A Extra Bolagsstämma 2025
2024-08-30 - Kvartalsrapport 2024-Q2
2024-04-12 - X-dag ordinarie utdelning TRMED 0.00 NOK
2024-04-11 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning TRMED 0.00 NOK
2023-04-26 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-31 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning TRMED 0.00 NOK
2022-04-28 - Årsstämma
2022-03-01 - Bokslutskommuniké 2021
2021-11-18 - 15-10 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-04-28 - Årsstämma
2021-04-16 - X-dag ordinarie utdelning TRMED 0.00 NOK
2021-03-22 - Extra Bolagsstämma 2021
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-10-21 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning TRMED 0.00 NOK
2020-06-10 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-04-20 - X-dag ordinarie utdelning TRMED 0.00 NOK
2020-02-27 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-04-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2019-04-25 - Årsstämma
2019-02-18 - Extra Bolagsstämma 2019
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning TRMED 0.00 NOK
2018-05-30 - Årsstämma
2018-05-30 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-12-20 - Extra Bolagsstämma 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-10-12 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-31 - Kapitalmarknadsdag 2016
2016-05-20 - X-dag ordinarie utdelning TRMED 0.00 NOK
2016-05-19 - Årsstämma
2016-05-19 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-17 - Kapitalmarknadsdag 2015
2015-10-21 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-05-27 - Kvartalsrapport 2015-Q1
2015-03-09 - Årsstämma
2014-11-12 - Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2022-11-03 14:01:29
Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody
Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH
Annual Meeting

Oslo, Norway, 3 November 2022

Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company")
announces the progress it has made in designing and developing a portfolio of
novel and potent humanized anti-CD37 monoclonal antibodies with potential for
treating B-cell malignancies or B-cell-driven autoimmune disorders.

Details of the Company's progress in engineering this portfolio are included in
two abstracts published today for presentation as posters at the 64[th] American
Society of Hematology (ASH) Annual Meeting & Exposition (10-13 December 2022 in
New Orleans, LA, USA). The abstracts will also be published online in a November
supplemental issue of Blood, published by The American Society of Hematology.

The abstracts describe how, through antibody engineering, Nordic Nanovector has
developed several humanized anti-CD37 monoclonal antibodies and demonstrated in
preclinical studies their enhanced effector mechanisms, such as antibody
-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP) and longer half-life in the blood.

CD37 is a protein abundant on the surface of B cells but absent in
haematopoietic stem cells and plasma cells. Its expression pattern makes it
attractive as a therapeutic target for B-cell malignancies, including non
-Hodgkin lymphomas and chronic lymphocytic Leukemia and for B-cell-driven
autoimmune disorders, especially where an alternative to standard anti-CD20
immunotherapy is sought.

Jostein Dahle, Co-founder and CSO of Nordic Nanovector, commented: "We are
pleased to present at ASH the initial findings from our preclinical studies with
our novel humanized anti-CD37 antibody portfolio. These antibodies have been
designed to be highly selective for CD37 on B cells and shown to be potent at
depleting these cells as well as enduring in the circulation. There is a
significant unmet clinical need for new therapeutic approaches for patients with
B-cell-driven diseases who do not respond to anti-CD20 therapies. The
encouraging preclinical results we will present at ASH support the further
development of these candidates for B-cell malignancies or B-cell-driven
autoimmune disorders."

Details of the abstracts to be presented at ASH are as follows:

Abstract 1351

Abstract title:                 NNV024, a Humanized Anti-CD37 Antibody with
Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell
Malignancies

Authors:                        R. Generalov et al.

Session Name:              605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster I

Date:                            Saturday, December 10

Presentation Time:        5:30 PM - 7:30 PM Eastern time

Location:                       Ernest N. Morial Convention Center, Hall D

Abstract 2679

Abstract title:                 B-Cell Targeting Anti-CD37 Humanized Antibodies
Engineered for Potent Effector Functions and Extended Plasma Half-Life

Authors:                        E. Fiorito et al.

Session Name:              605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster II

Session Date:               Sunday, 11 December

Presentation Time:        6:00 PM - 8:00 PM Eastern time

Location:                      Ernest N. Morial Convention Center, Hall D

IR enquiries

Malene Brondberg, interim CEO & CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company's clinical- and preclinical-stage pipeline includes:

· Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies
incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma
(NHL)